Task Force II: blood pressure measurement and cardiovascular outcome.
about
Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review.Cognitive and autonomic dysfunction measures in normal controls, white coat and borderline hypertension.Association of polycystic ovary syndrome and a non-dipping blood pressure pattern in young women.Do dispositional pessimism and optimism predict ambulatory blood pressure during school days and nights in adolescents?Racial differences in the impact of social support on nocturnal blood pressure.Diagnostic value and cost-benefit analysis of 24 hours ambulatory blood pressure monitoring in primary care in PortugalBlood pressure measurement guidelines for physical therapists.Differing pattern of ambulatory blood pressure in very elderly men expresses dynamics in atherosclerotic load in the senescence.Ambulatory blood pressure monitoring in the elderly.Out-of-office blood pressure: from measurement to controlBlood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP).Associations between nocturnal blood pressure dipping and the metabolic syndrome in high- vs. low-acculturated Mexican American women.Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study.Does reducing physician uncertainty improve hypertension control?: rationale and methods.Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes.Hypertension in the teenager.Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration stuIs Daytime Systolic Load an Important Risk Factor for Target Organ Damage in Pediatric Hypertension?Sesame oil consumption exerts a beneficial effect on endothelial function in hypertensive men.Candesartan cilexetil effectively reduces blood pressure in hypertensive children.Home blood pressure monitoring among adults-American Heart Association Cardiovascular Health Consumer Survey, 2012.Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release.Blood pressure abnormalities in children with sickle cell anemia.The differential diagnostic value of serum homocysteine for white coat hypertension.Diagnostic value of strategy for the detection of white coat hypertension based on ambulatory and home blood pressure monitoring.Twenty-four-hour ambulatory blood pressure in children with sleep-disordered breathing.Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.Large-scale ensemble averaging of ambulatory impedance cardiograms.Non-invasively estimated end-systolic elastance in patients with resistant hypertension and type 2 diabetes mellitus.Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm.Relationships of different blood pressure categories to indices of inflammation and platelet activity in sustained hypertensive patients with uncontrolled office blood pressure.Regular use of a home blood pressure monitor by hypertensive adults--HealthStyles, 2005 and 2008.Cerebral microbleeds and blood pressure abnormalities in Parkinson's disease.2007 ESH‐ESC Guidelines for the management of arterial hypertension
P2860
Q33715998-B7E9F003-6868-4B0E-974E-37D8930CCEF2Q33790427-897324B8-5DAB-4999-A8D0-485ED8F6456FQ33901117-705E7F21-98F2-4903-9AF0-333B4D472F69Q34058764-A67B221A-8631-418B-B179-1FD1FABBB892Q34703440-8EE7DF18-07F5-468B-ADDC-64BE32D0590BQ34927938-E174AC2C-FEE5-4F0C-970F-22755206EADCQ35016318-5044952F-EDED-4194-B204-321A4265E183Q35636169-4240C4C7-1765-4A08-9708-CE680330B1FCQ35646532-50732589-5814-4FA0-9F27-5FB1CCB7D4E8Q35997369-265A6A3B-C8E7-4210-85A0-6062AFC6ABB9Q36158003-626D2DE3-980B-4FFD-8BA8-7A00FCC9AF48Q36996453-75594F38-8020-4202-8AF3-3F79CED87CE4Q37246776-EBC3B0A0-7215-489F-9A14-0971954717DDQ37428080-0DAFCFF1-077F-46E8-94FE-07766808D7E0Q37435002-2141005E-0A05-476C-B1E6-8C6086BF896EQ37627388-7FA2732D-92E7-4774-8944-C62BAB87CE70Q38104812-7B5C4D28-145F-492A-90C3-243B413B2896Q38490084-0BF28694-1AC0-4DCC-8F09-CAA447AF9D90Q40770977-8B9343A4-C6B4-47DD-8BF3-84C519BB8D39Q42156423-032EC5D4-6883-4447-B2E4-13C11E30C8C1Q42663516-752AF08B-CCB8-4BC5-84E8-D34E32D0B916Q43666151-0848FFB7-71EA-45EA-83B2-7831CBC5F761Q46591727-4291A8F6-EE9C-4E00-8288-584AA7DDB677Q46620043-C8CC1929-B1D1-4FF3-98B9-9E57439388B4Q47103738-A495556E-25C4-40C6-B231-7E3188065A90Q47256633-4DA8EF97-CEA8-44C4-94F8-938F204EC1D7Q48022686-EB6E895C-E329-4CF3-9421-93235500A1FFQ48151085-90C1A2FB-4860-4737-8F98-D40A9E978899Q48614592-514AFF6F-CFC8-4B2D-8F3C-EDF338759081Q49124140-730D63C4-0099-42D0-AA8F-A3DF634D1633Q50648369-75DC426A-B5C2-4960-BC22-DECA78706007Q50852271-0E48F178-B8DE-4DE9-8152-CD9E0CFB2607Q53654659-333CF471-0287-4FA1-9DA3-B08F78C43139Q55024081-388B2244-5E17-460A-AB6A-79257A85389AQ56970799-01530C13-4A1C-43A7-A49E-754542F3F33E
P2860
Task Force II: blood pressure measurement and cardiovascular outcome.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Task Force II: blood pressure measurement and cardiovascular outcome.
@ast
Task Force II: blood pressure measurement and cardiovascular outcome.
@en
Task Force II: blood pressure measurement and cardiovascular outcome.
@nl
type
label
Task Force II: blood pressure measurement and cardiovascular outcome.
@ast
Task Force II: blood pressure measurement and cardiovascular outcome.
@en
Task Force II: blood pressure measurement and cardiovascular outcome.
@nl
prefLabel
Task Force II: blood pressure measurement and cardiovascular outcome.
@ast
Task Force II: blood pressure measurement and cardiovascular outcome.
@en
Task Force II: blood pressure measurement and cardiovascular outcome.
@nl
P2093
P50
P1476
Task Force II: blood pressure measurement and cardiovascular outcome
@en
P2093
M De Buyzere
P Verdecchia
Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring
P304
P356
10.1097/00126097-200112000-00016
P577
2001-12-01T00:00:00Z